HB 2208 would add a new section to Arizona law governing pharmacy benefit managers (PBMs) and how they reimburse contracted pharmacies and pharmacists for prescription drugs and devices. The bill requires PBMs to reimburse at or above the pharmacy’s actual acquisition cost, prohibits PBMs from counting professional dispensing fees toward meeting that floor, and requires PBMs to pay a dispensing fee at least as high as the fee-for-service methodology used in Arizona’s Medicaid program (AHCCCS), unless the PBM already uses an identical ingredient-cost methodology approved under federal Medicaid rules.
The bill also creates a formal appeal process for pharmacies that believe they were underpaid. PBMs must include appeal procedures in contracts, file those procedures with the Department of Insurance and Financial Institutions, and allow pharmacies or their agents, including pharmacy services administrative organizations, to file appeals. If a pharmacy wins an appeal, the PBM must correct the reimbursement, provide drug-identification information, allow reverse-and-rebill processing, reimburse actual cost, and extend the appeal result to similarly situated pharmacies. If the PBM wins, it must identify a wholesaler and product code for a source priced at or below the challenged reimbursement when available. The law would apply only to contracts entered into, amended, extended, or renewed on or after December 31, 2025.
Impact
HB 2208 would impose new reimbursement and claims-processing requirements on pharmacy benefit managers operating in Arizona, directly affecting PBM contracts with pharmacies and pharmacists. It would also create administrative oversight by requiring PBM appeal procedures to be filed with and approved by the state department, and it would give pharmacies a statutory mechanism to challenge reimbursement rates and obtain retroactive corrections. The bill excludes certain state-procured health and accident coverage under section 38-651 and defines key terms such as “state plan” by reference to AHCCCS.
Sentiment
The available voting history suggests the bill was received favorably in committee, passing the House Health & Human Services Committee 9-0 with a do-pass recommendation. No committee transcript was provided, so there is no recorded debate to indicate broader support or opposition beyond the unanimous committee vote. Based on the bill’s structure, the measure appears aimed at addressing pharmacy reimbursement concerns and protecting pharmacies from being paid below cost.
Contention
The main policy tension in HB 2208 is between pharmacies, which would benefit from higher reimbursement floors and a stronger appeal process, and PBMs, which would face tighter reimbursement limits, new disclosure obligations, and potential administrative burdens. A likely point of contention is the bill’s requirement that PBMs pay at least the actual cost plus a dispensing fee tied to AHCCCS methodology, as well as the mandate to apply successful appeals to similarly situated pharmacies. Another possible issue is the short seven-business-day appeal window and the requirement that PBMs provide wholesaler and drug-code information when they prevail, which may raise operational and compliance concerns for PBMs and insurers.
Regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)